The price-to-earnings ratio for Sanofi ADR (NASDAQ: SNY) is above average at 31.47x. The 36-month beta value for SNY is also noteworthy at 0.57. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for SNY is 2.51B, and at present, short sellers hold a 0.43% of that float. The average trading volume of SNY on September 25, 2024 was 1.99M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
SNY) stock’s latest price update
The stock of Sanofi ADR (NASDAQ: SNY) has decreased by -0.93 when compared to last closing price of 57.62.Despite this, the company has seen a loss of -0.67% in its stock price over the last five trading days. reuters.com reported 2024-09-24 that Sanofi has received two separate bids for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion) or more, from private equity firms Clayton Dubilier & Rice and PAI Partners, Bloomberg News reported on Tuesday.
SNY’s Market Performance
Sanofi ADR (SNY) has experienced a -0.67% fall in stock performance for the past week, with a 1.45% rise in the past month, and a 18.12% rise in the past quarter. The volatility ratio for the week is 1.01%, and the volatility levels for the past 30 days are at 1.02% for SNY. The simple moving average for the past 20 days is -0.52% for SNY’s stock, with a 13.99% simple moving average for the past 200 days.
Analysts’ Opinion of SNY
Many brokerage firms have already submitted their reports for SNY stocks, with Argus repeating the rating for SNY by listing it as a “Buy.” The predicted price for SNY in the upcoming period, according to Argus is $60 based on the research report published on July 26, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see SNY reach a price target of $55. The rating they have provided for SNY stocks is “Equal-Weight” according to the report published on January 23rd, 2024.
SNY Trading at 4.72% from the 50-Day Moving Average
After a stumble in the market that brought SNY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.19% of loss for the given period.
Volatility was left at 1.02%, however, over the last 30 days, the volatility rate increased by 1.01%, as shares surge +1.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +13.93% upper at present.
During the last 5 trading sessions, SNY fell by -0.78%, which changed the moving average for the period of 200-days by +23.80% in comparison to the 20-day moving average, which settled at $57.42. In addition, Sanofi ADR saw 14.79% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for SNY
Current profitability levels for the company are sitting at:
- 0.22 for the present operating margin
- 0.66 for the gross margin
The net margin for Sanofi ADR stands at 0.12. The total capital return value is set at 0.15. Equity return is now at value 5.80, with 3.31 for asset returns.
Based on Sanofi ADR (SNY), the company’s capital structure generated 0.23 points at debt to capital in total, while cash flow to debt ratio is standing at 0.37. The debt to equity ratio resting at 0.3. The interest coverage ratio of the stock is 10.13.
Currently, EBITDA for the company is 12.96 billion with net debt to EBITDA at 0.84. When we switch over and look at the enterprise to sales, we see a ratio of 2.14. The receivables turnover for the company is 7.71for trailing twelve months and the total asset turnover is 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.00.
Conclusion
In summary, Sanofi ADR (SNY) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
